Intestinal microbiota: The explosive mixture at the origin of inflammatory bowel disease?

Table 2 Probiotic therapy in inflammatory bowel diseases

Model	Probiotic	Effect
Trinitrobenzene sulphonic acid or dinitrobenzene sulphonic acid	Bi. infantis	No effect
	L. acidophilus, L. casei and Bi. animalis	Reduced inflammation
	VSL#3	No effect
	Lactobacillus GG	No effect
	L. plantarum 299	No effect
	VSL#3 (DNA, subcutaneously)	Reduced inflammation
Iodoacetamide	VSL#3	Reduced inflammation
	Lactobacillus GG	Reduced inflammation
Acetic acid	L. rhamnosus GG	No effect
	L. reuteri R2LC	Reduced inflammation
	L. reuteri R2LC	Reduced inflammation
Dextran sodium sulphate	VSL#3 (irradiated and DNA*)	Reduced inflammation
IL-10 knockout mice	L. salivarius 118 (subcutaneously)	Reduced inflammation
	L. salivarius	Reduced inflammation
	Bi. infantis	Reduced inflammation
	L. plantarum 299V	Reduced inflammation
	VSL#3	Reduced inflammation
	L. salivarius	Reduced inflammation
	L. reuteri	Reduced inflammation
	VSL#3 (DNA, subcutaneously)	Reduced inflammation
E. coli-induced colitis in IL-2 knockout mice	B. vulgatus	Reduced inflammation
B. vulgatus-induced colitis	Lactobacillus GG	Prevented recurrent colitis
	L. plantarum 299V	No prevention of recurrent colitis